PulseAugur
LIVE 10:38:46
research · [1 source] · · 中文(ZH) 百济神州:2026年第一季度净利润16.08亿元
0
research

BeiGene posts Q1 profit of 1.6B yuan on strong drug sales

BeiGene announced its financial results for the first quarter of 2026, reporting a net profit attributable to parent company owners of 1.608 billion yuan. This marks a significant turnaround from a loss in the same period last year. The company's revenue grew by 31.0% year-over-year to 10.544 billion yuan, primarily driven by strong sales of its key products, including BeiYueZe®, authorized products from Amgen, and BeiZeAn®. AI

Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →

RANK_REASON Financial results announcement from a major company. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    BeiGene: Net profit of 1.608 billion yuan in the first quarter of 2026

    36氪获悉,百济神州公告,公司2026年第一季度实现营业总收入105.44亿元,同比增长31.0%;产品收入103.21亿元,同比增长29.3%;归属于母公司所有者的净利润16.08亿元,上年同期为亏损。业绩增长主要得益于百悦泽®、安进公司授权产品及百泽安®的销售增长。